XALKORI 200 mg hard capsules
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Bristol-Myers Squibb Services Unlimited Company, F. Hoffmann-La Roche AG, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Pfizer Inc.
Conditions
Advanced solid tumorAnaplastic Large Cell Lymphoma (ALCL)Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)Inflammatory Myofibroblastic Tumors (IMT)Multiple myelomaNeuroblastoma (NBL)Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign peripheral nervous system tumors and various benign or locally malignant tumors of the central nervous system.
Many complications occur in children more often than in adults and significantly shorten the survival period of affected children.Non small cell lung cancer (NSCLC)
Phase 1
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded from surgery and / or radiotherapy
RecruitingCTIS2024-516607-16-00
Start: 2024-01-17Target: 1Updated: 2025-05-12
Phase 3
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1 positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
RecruitingCTIS2023-505604-32-00
Start: 2024-01-24Target: 83Updated: 2025-09-15
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements with and Without Central Nervous System Metastases
RecruitingCTIS2023-507494-18-00
Start: 2021-09-24Target: 91Updated: 2026-01-20
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
CompletedCTIS2023-506859-13-00
Start: 2014-09-09End: 2025-03-14Target: 51Updated: 2025-04-22
eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Active, not recruitingCTIS2024-513454-29-00
Start: 2015-10-15Target: 47Updated: 2025-06-05